IP Library › Granted Patent US 11,306,057
Granted Patent B2
US 11,306,057 · App. 16/878,507 · Granted Apr 19, 2022

Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms

Inventor: Michael E. Silver (Lake City, MI)
Assignee: The William M. Yarbrough Foundation
C07C331/20A61K9/0014A61K31/145A61K31/198A61K31/26A61K45/06A61K47/34A61K9/06A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,306,057
App. No.
16/878,507
Granted
Apr 19, 2022
Kind
B2
Abstract

The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms. One suitable isothiocyanate functional surfactant is represented by the following chemical structure:

Claims (8)

1. A method, comprising the step of administering to a patient having a biofilm an isothiocyanate functional surfactant, wherein the surfactant comprises a lysine derivative having an α-nitrogen and a ϵ-nitrogen, and wherein an alkyl substituent comprising at least 8 carbon atoms is bound to the α-nitrogen, and further wherein the ϵ-nitrogen forms part of an isothiocyanate functional group.

2. The method according to claim 1 , wherein the composition comprising the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, vaginally, ocularly, otically, and nasally.

3. The method according to claim 1 , wherein the composition comprising the isothiocyanate functional surfactant is topically administered to the patient.

4. The method according to claim 3 , wherein the amount of isothiocyanate functional surfactant in the composition topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μmol/cm2.

5. The method according to claim 4 , wherein the composition comprising the isothiocyanate functional surfactant is a topical preparation selected from the group consisting of ointment, cream, emulsion, lotion and gel.

6. The method according to claim 5 , wherein the composition further comprises one or more pharmaceutical, biological or molecular biological active agents.

7. The method according to claim 1 , wherein the patient is a mammal.

8. The method according to claim 1 , wherein the mammal is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2020
From: SILVER, MICHAEL E.
To: THE WILLIAM M. YARBROUGH FOUNDATION
Reel/Frame 054009/0302 →
Continuity (10)
Continuation 16411398 · May 14, 2019
Continuation 15890578 · Feb 7, 2018
Continuation 15786757 · Oct 18, 2017
Continuation In Part 15353260 · Nov 16, 2016
Continuation 15297304 · Oct 19, 2016
Continuation 14594788 · Jan 12, 2015
Continuation 13342516 · Jan 3, 2012
Provisional Application 61502067 · Jun 28, 2011
Provisional Application 61429325 · Jan 3, 2011
Related Publication 20210024463A1 · Jan 28, 2021
Cited By (2)
US 12,239,626 US 12,310,939